CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 608 enrolled
Drug / intervention
Losartan Potassium +1 moredrug
Likely dose
Losartan Potassium 1.4 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00429364
NCT00429364Phase 3Completed
CompareCT.gov

Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)

Carelon Research·interventional·Posted Jan 31, 2007·Updated Mar 7, 2025

In Brief

A Phase 3 clinical trial evaluating Losartan Potassium and Atenolol for Marfan Syndrome. Completed, enrolled 608 participants across 26 sites in 3 countries.

Detailed Summary

Marfan syndrome is a hereditary connective tissue disorder. Many individuals with this condition die because of the associated heart and blood vessel abnormalities. This study will compare the effectiveness of two medications, losartan and atenolol, at slowing aortic root enlargement in individuals with Marfan syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarfan Syndrome
CountriesBelgium, Canada, United States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), FDA Office of Orphan Products Development, National Marfan Foundation

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 31, 2007
Enrollment StartJan 1, 2007
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 19.4 years ago

Interventions

Losartan Potassiumdrug

Losartan .3 - 1.4 mg/kg

Atenololdrug

Atenolol .5 - 4 mg/kg